Although GLP-1 RAs appear to have a neutral effect on cardiac arrhythmias, a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) by Thotamgari et al. indicated that linagliptin was associated with the highest proportion of AF events in diabetic patients. The gene discussed is GCG; the disease is cardiac arrhythmia.